Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Manabu, Iwasaki"'
Autor:
Naoki Ikegaya, Honoka Nakamura, Yutaro Takayama, Yohei Miyake, Takahiro Hayashi, Masaki Sonoda, Mitsuru Sato, Kensuke Tateishi, Jun Suenaga, Masao Takaishi, Yu Kitazawa, Misako Kunii, Hiroki Abe, Tomoyuki Miyazaki, Tetsuaki Arai, Manabu Iwasaki, Takayuki Abe, Tetsuya Yamamoto
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 10, Iss 3, Pp n/a-n/a (2024)
Abstract INTRODUCTION The use of anti‐epileptic drugs (AEDs) in degenerative dementia (DD) remains uncertain. We aimed to evaluate the association of early AED administration with subsequent DD occurrence. METHODS Using a large nationwide database,
Externí odkaz:
https://doaj.org/article/a9e3e85dd375488d89766625af530235
Autor:
Ichiei Narita, Terumasa Hayashi, Shoichi Maruyama, Takao Masaki, Masaomi Nangaku, Tomoya Nishino, Hiroshi Sato, Tadashi Sofue, Takashi Wada, Enyu Imai, Manabu Iwasaki, Kyoichi Mizuno, Hiroki Hase, Masahiro Kamouchi, Hiroyasu Yamamoto, Tatsuo Kagimura, Kenichiro Tanabe, Hideki Kato, Takehiko Wada, Tomoko Usui, Tadao Akizawa, Hideki Hirakata, Yoshiharu Tsubakihara
Publikováno v:
PLoS ONE, Vol 17, Iss 11, p e0277921 (2022)
Among non-dialysis-dependent chronic kidney disease (ND-CKD) patients, a low hematopoietic response to erythropoiesis-stimulating agents (ESAs) is a predictor for poor renal and cardiovascular outcome. To assess the method for evaluating hyporesponsi
Externí odkaz:
https://doaj.org/article/2e61b3508b6348a18fef1530569eede2
Autor:
Manabu, Iwasaki
Publikováno v:
Japanese Journal of Statistics and Data Science. 5:721-724
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46b7ce8a9ec968ff57e5aefc9e624cdf
https://doi.org/10.1007/s42081-022-00180-0
https://doi.org/10.1007/s42081-022-00180-0
Autor:
Manabu Iwasaki
Publikováno v:
Ouyou toukeigaku. 51:43-54
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b52751dda3c04fd7242868e6c47318e5
https://doi.org/10.5023/jappstat.51.43
https://doi.org/10.5023/jappstat.51.43
Publikováno v:
Kidney International Reports
Introduction Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated safety and efficacy versus placebo in phase III trials in patients with anemia of chronic kidney disease (CKD) who were not on dialysis (ND
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a861e6689271ef9dcda7394262c63ba
https://doi.org/10.1016/j.ekir.2021.04.003
https://doi.org/10.1016/j.ekir.2021.04.003
Publikováno v:
Ouyou toukeigaku. 50:103-124
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b6896f456aac098459f2e726f6e45f9
https://doi.org/10.5023/jappstat.50.103
https://doi.org/10.5023/jappstat.50.103
Publikováno v:
J Am Soc Nephrol
Background Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in China for dialysis-dependent CKD anemia. Methods This phase 3, 24-week, double-blind, double-dummy study evaluated roxadustat's noninferiority to darbe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c27810510e223d17067123b3ce20b65
https://doi.org/10.1681/asn.2019060623
https://doi.org/10.1681/asn.2019060623
Publikováno v:
Journal of the American Society of Nephrology. 32:1005-1007
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ff0e1e62d6de190f73a131f49d21a92
https://doi.org/10.1681/asn.2021010051
https://doi.org/10.1681/asn.2021010051
Publikováno v:
J Am Soc Nephrol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd60f4e52b72cf7ce5d283d7cec9f1dc
https://doi.org/10.1681/asn.2020071096
https://doi.org/10.1681/asn.2020071096
Autor:
Yeong Wook Song, Manabu Iwasaki, Tsutomu Takeuchi, James Cheng-Chung Wei, Yuichiro Kaneko, Yoshiya Tanaka, Satoshi Ushijima, Rio Akazawa, Emi Yamada, Sang-Heon Lee, Mitsuhiro Rokuda, Yi Hsing Chen, Teruaki Shiomi, Hiroyuki Izutsu, Sakae Tanaka, Atsushi Kawakami
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesTo investigate the efficacy and safety of peficitinib, an oral Janus kinase inhibitor, in patients with rheumatoid arthritis (RA).MethodsIn this double-blind phase III study, patients with RA and an inadequate response to prior disease-modi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56406f5a17409c934613c80065f2f965
http://europepmc.org/articles/PMC6788921
http://europepmc.org/articles/PMC6788921